FDA Expands Lilly's ERBITUX® (cetuximab) Label with Com

FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy

FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy

prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , United Kingdom , America , American , British , Kevin Hern , David Hyman , Eli Lilly , Tracy Henrikson , Safaee Ardekani , Exchange Commission , Pfizer , Pfizer Inc , Drug Administration , Lilly United States , American Cancer Society , North America , South America , Asia Pacific , Accompanying Electrolyte , Tumor Progression , Increased Mortality , Prescribing Information , Boxed Warnings , Private Securities Litigation Reform Act , United States Securities , Cancer Facts , American Cancer , Accessed July , Mutation Analysis , Metastatic Colorectal Cancer , Daily Clinical Practice , Clinical Characteristics , Its Impact , Marked Survival Differences , Subgroups According , Tumor Tissue Availability , Colon Cancers , Potential Clinical ,